Journal
Blood Advances
Publication Date
7-25-2023
Volume
7
Issue
14
First Page
3582
Last Page
3591
Document Type
Open Access Publication
DOI
10.1182/bloodadvances.2022009311
Rights and Permissions
Verstovsek S, Mesa R, Gupta V, Lavie D, Dubruille V, Cambier N, Platzbecker U, Hus M, Xicoy B, Oh ST, Kiladjian JJ, Vannucchi AM, Gerds A, Egyed M, Mayer J, Sacha T, Kawashima J, Morris M, Huang M, Harrison C. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials. Blood Adv. 2023 Jul 25;7(14):3582-3591. doi: 10.1182/bloodadvances.2022009311. © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Recommended Citation
Verstovsek, Srdan; Oh, Stephen T; and et al., "Momelotinib long-term safety and survival in myelofibrosis: Integrated analysis of Phase 3 randomized controlled trials." Blood Advances. 7, 14. 3582 - 3591. (2023).
https://digitalcommons.wustl.edu/oa_4/2206
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
